financetom
Business
financetom
/
Business
/
Bain proposes Japan's Kioxia IPO to clear $5.8 bln loan refinance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bain proposes Japan's Kioxia IPO to clear $5.8 bln loan refinance
Apr 16, 2024 5:34 AM

TOKYO, April 16 (Reuters) - Bain Capital has proposed an

initial public offering (IPO) of Japan's Kioxia Holdings as part

of a plan to allow the money-losing chipmaker to refinance a

$5.8 billion loan coming due in June, according to a person

familiar with the matter.

Bain and Kioxia met with a group of banks including Sumitomo

Mitsui, Mizuho and Mitsubishi UFJ on

Monday after the lenders urged Kioxia to come up with a

recapitalisation plan because it looks likely to run afoul of

the terms of a 900 billion yen ($5.8 billion) syndicated loan,

the person said.

Formerly Toshiba Memory, Kioxia was acquired by a Bain-led

group in a $18 billion carve-out in 2018. The maker of memory

chips is expected to have posted a loss for the year that ended

last month, according to the person. That would mark its second

straight annual loss and push its net assets below the roughly

500 billion yen required under the terms of the loan, the person

said.

Under the plan presented to the banks, Kioxia expects to

return to profit in the year to March 2025, seeing earnings of

around 130 billion yen.

The person declined to be identified because the information

has not been made public. Details of Kioxia's finances were

confirmed in a review of the plan presented to banks by Reuters.

Kioxia, Mizuho and Mitsubishi UFJ declined to comment.

Sumitomo Mitsui did not immediately reply to a request for

comment. Bain could not immediately be reached for comment.

It was not immediately clear if the banks had accepted the

proposal. The timing of the proposed listing was also not clear,

though the person said it would come after the June refinancing.

Kioxia would also need to present a convincing growth plan

to future investors, the person said.

Kioxia, which been hammered by a slump in the market for

memory chips, remains a prominent chipmaker even as Japan has

ceded influence in the sector to Taiwan and South Korea.

The Japanese government aims to revive the country's lost

position as a major chipmaking centre and is extending subsidies

to Kioxia and other companies.

There are also been some signs of a pick-up in demand for

the memory market.

The banks want the refinancing to pave the way for reviving

merger talks with U.S. chipmaker Western Digital ( WDC ),

according to the source.

Talks between the two to merge and create a memory chip

powerhouse stalled last year due to opposition from South

Korea's SK Hynix, which is an investor in Kioxia.

The banks had previously pledged to provide a loan of about

1.9 trillion yen on the condition that Kioxia would merge with

Western Digital ( WDC ).

($1 = 154.5300 yen)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update On ATS; National Bank Says Co Has
Update On ATS; National Bank Says Co Has "Turned the Corner" Despite Q3 Miss
Feb 5, 2025
10:27 AM EST, 02/05/2025 (MT Newswires) -- (Updates with National Bank commentary in the 5th and 6th paragraphs and shares in the last paragraph) ATS , an automation solutions provider, rose more than 7% on Wednesday despite reporting lower-than-expected third quarter earnings. Adjusted basic earnings per share fell to $0.32 cents, compared with $0.65 cents a year ago, missing a...
Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage
Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage
Feb 5, 2025
10:22 AM EST, 02/05/2025 (MT Newswires) -- Vaxcyte ( PCVX ) said Wednesday its ongoing phase 2 study assessing VAX-31 for the prevention of invasive pneumococcal disease in infants is advancing to its second and final stage. The company said participants who received VAX-31 in the first stage will continue the standard dosing regimen as part of the second stage....
Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2
Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2
Feb 5, 2025
10:27 AM EST, 02/05/2025 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said Wednesday its UX111 gene therapy led to a statistically significant improvement in cognition, receptive communication and expressive communication among patients with Sanfilippo syndrome type A compared with natural history data in untreated patients with the rare genetic disorder that affects the brain and spinal cord. According to...
Cloudflare Seeks Federal Certifications in US, Australia for Cybersecurity
Cloudflare Seeks Federal Certifications in US, Australia for Cybersecurity
Feb 5, 2025
10:24 AM EST, 02/05/2025 (MT Newswires) -- Cloudflare ( NET ) is seeking federal certifications in the US and Australia to meet stringent security standards across government and critical infrastructure sectors Services and technology are in process for the Federal Risk and Authorization Management Program High, the top level of security control for US federal government cloud services, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved